Alterity Therapeutics Limited

OTCPK:PRNA.F Stock Report

Market Cap: US$53.1m

Alterity Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:PRNA.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
07 Apr 25BuyUS$14,927Brian MeltzerIndividual2,272,727US$0.0066
07 Apr 25BuyUS$29,855Lawrence GozlanIndividual4,545,455US$0.0066
07 Apr 25BuyUS$11,942Peter MarksIndividual1,818,182US$0.0066
31 Mar 25BuyUS$2,363,281Regal Partners LimitedCompany339,404,840US$0.007
20 Mar 25SellUS$56,017JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany8,900,000US$0.0063
14 Feb 25BuyUS$638,529JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany101,417,911US$0.0064
03 Feb 25SellUS$199,059JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany31,006,034US$0.011
30 Jan 25BuyUS$2,021,773JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany217,910,474US$0.011

Insider Trading Volume

Insider Buying: PRNA.F insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PRNA.F?
Owner TypeNumber of SharesOwnership Percentage
Private Companies137,842,8581.51%
Individual Insiders300,214,4683.29%
Hedge Funds1,255,948,17913.8%
Institutions2,942,665,65032.2%
General Public4,490,699,53149.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 74%.

Top Shareholders

Top 25 shareholders own 50.62% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
25%
BNY Asset Management
2,277,308,548US$13.3m9.77%no data
13.8%
Regal Partners Limited
1,255,948,179US$7.3m585%0.38%
3.6%
JPMorgan Chase & Co, Brokerage and Securities Investments
328,851,614US$1.9m166%no data
1.37%
Merrill Lynch & Co. Inc., Banking Investments
125,280,000US$729.4k0%no data
0.71%
Carl Charalambous
65,000,000US$378.4k0%no data
0.58%
Mst Financial Services Pty Ltd, Asset Management Arm
52,517,122US$305.7k0%70.75%
0.48%
Andrew Seton
44,203,475US$257.3k0%no data
0.47%
One Managed Investment Funds Limited
42,857,143US$249.5k0%0.28%
0.44%
The Hartman Investment
40,000,000US$232.9k0%no data
0.42%
Jagen Pty Ltd
38,556,497US$224.5k0%4.0%
0.41%
Lan Au Buu
37,211,096US$216.6k0%no data
0.39%
M F Cunningham Pty Ltd
35,571,429US$207.1k0%no data
0.35%
Satur Investments Pty Ltd
32,271,429US$187.9k0%no data
0.33%
Spiceme Capital Pty Ltd
30,000,000US$174.7k0%no data
0.31%
Craig Chapman
28,571,429US$166.3k0%no data
0.31%
Elif Gunes
28,571,429US$166.3k0%no data
0.29%
Morgan Stanley, Investment Banking and Brokerage Investments
26,631,000US$155.0k-0.22%no data
0.28%
Scott Nicholls
26,000,000US$151.4k0%no data
0.21%
Point72 Asset Management, L.P.
19,576,200US$114.0k0%no data
0.21%
HB Wealth Management, LLC
19,129,800US$111.4k34.1%no data
0.2%
Geoffrey Kempler
18,011,000US$104.9k21.7%no data
0.16%
Kim Muller
14,677,092US$85.4k0%no data
0.16%
Jeffrey Keller
14,677,092US$85.4k0%no data
0.11%
Brian Meltzer
9,742,250US$56.7k30.4%no data
0.099%
Peter Marks
9,004,150US$52.4k25.3%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/05 15:27
End of Day Share Price 2025/04/15 00:00
Earnings2024/12/31
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alterity Therapeutics Limited is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert WassermanBenchmark Company
George ZavoicoB. Riley Securities, Inc.
Vernon BernardinoFBR Capital Markets & Co.